Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma III: Clinical Manifestations01:13

Asthma III: Clinical Manifestations

Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...
Antiasthma Drugs: Methylxanthines01:24

Antiasthma Drugs: Methylxanthines

Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Previable Preterm Premature Rupture of the Membranes Reaching Viability: Canadian Outcomes.

Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC·2026
Same author

Investigating the association of fetal sex and hypertensive pregnancy outcomes across varying conception types: a retrospective cohort study.

Journal of gynecology obstetrics and human reproduction·2026
Same author

Clinicoradiological and Histopathological Correlation of Placenta Accreta Spectrum (PAS).

Journal of obstetrics and gynaecology of India·2026
Same author

Contribution of astrocytic calcium signaling to auditory hypersensitivity in a mouse model of fragile X syndrome.

Neurobiology of disease·2026
Same author

Science communication tools: rubrics for generating posters and manuscripts that are authentic to the practice of science.

Journal of microbiology & biology education·2026
Same author

Designing Biochemical Visual Literacy Assessments: Insights from Classroom Testing and Student Interviews.

Journal of chemical education·2026

Related Experiment Video

Updated: Jun 8, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Omalizumab for pediatric asthma.

Robert G Townley1, Swati Agrawal, Kiran Sapkota

  • 1Division of Asthma, Creighton University Medical Center, 601 N, 30th ST, Suite 3M100, Omaha, NE 68131, USA. rtownley@creighton.edu

Expert Opinion on Biological Therapy
|October 20, 2010
PubMed
Summary
This summary is machine-generated.

Omalizumab effectively treats severe allergic asthma in adults and children by inhibiting immunoglobulin E (IgE). This reduces reliance on corticosteroids and hospitalizations, though cardiovascular effects are under investigation.

More Related Videos

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
05:31

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels

Published on: August 7, 2017

Related Experiment Videos

Last Updated: Jun 8, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
05:31

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels

Published on: August 7, 2017

Area of Science:

  • Immunology
  • Pharmacology
  • Allergy and Asthma Treatment

Background:

  • Severe allergic asthma is a significant health concern.
  • Omalizumab targets the immunoglobulin E (IgE) pathway.
  • Current FDA approval excludes children under 12, despite demonstrated efficacy.

Purpose of the Study:

  • To review the efficacy and safety of omalizumab for severe asthma.
  • To clarify the mechanism of action of omalizumab.
  • To discuss the current regulatory status and potential side effects.

Main Methods:

  • Review of existing literature on omalizumab.
  • Analysis of FDA statements and manufacturer data.
  • Examination of omalizumab's binding to IgE and FcϵRI.

Main Results:

  • Omalizumab demonstrates proven efficacy in treating severe allergic asthma in both adults and children.
  • The drug significantly reduces the need for oral and inhaled corticosteroids.
  • Hospitalizations are decreased in patients treated with omalizumab.

Conclusions:

  • Omalizumab is an effective treatment for severe asthma, offering reduced corticosteroid dependence and hospitalizations.
  • A potential mechanism for omalizumab's cardiovascular effects, including thrombus formation, is proposed.
  • Further research is needed to fully understand omalizumab's long-term safety profile.